连续流左心室辅助装置桥接移植中的竞争风险
单中心回顾性分析2006至2020年 listed 患者(CF-LVAD 300例,原发移植244例),CF-LVAD组1年移植、除名、死亡率分别为48%、8%、2%,原发移植组为45%、15%、9%(均P<.001);5年等待名单死亡率CF-LVAD组4% vs 原发移植组13%;移植后生存无差异(P=.250)。
要点
- CF-LVAD组1年移植率48%,除名率8%,死亡率2%;原发移植组分别为45%、15%、9%(均P<.001)。
- 5年等待名单死亡率CF-LVAD组4%,原发移植组13%;listed后全因死亡率CF-LVAD组更低(P=.017)。
- 多因素Fine-Gray回归显示卒中(P=.017)、呼吸衰竭(P=.032)、右心衰竭(P=.019)和驱动缆感染(P=.050)与移植概率降低相关。
核心结论
- 尽管装置相关并发症与移植率降低显著相关,CF-LVAD患者的等待名单结局总体良好。
- 鉴于2018年分配评分变化,在决定是否提供CF-LVAD作为桥接移植时应考虑并发症风险。
研究设计与样本
- 单中心回顾性研究,纳入2006至2020年 listed 原位心脏移植患者,CF-LVAD组300例,原发移植组244例。
- 采用Kaplan-Meier法和log-rank检验评估生存结局;以死亡、除名和移植为竞争风险,用Gray检验比较组间差异;多因素Fine-Gray回归识别移植预测因素。
主要发现
- 1年移植、除名、死亡率CF-LVAD组分别为48%、8%、2%,原发移植组分别为45%、15%、9%(均P<.001)。
- 5年等待名单死亡率CF-LVAD组4%,原发移植组13%。
- listed后全因死亡率CF-LVAD组更低(P=.017);移植后生存两组无差异(P=.250)。
- 多因素Fine-Gray回归中卒中(P=.017)、呼吸衰竭(P=.032)、右心衰竭(P=.019)和驱动缆感染(P=.050)与移植概率降低相关。
- 发生装置相关并发症的CF-LVAD患者移植后生存未显著更差(P=.901)。
临床怎么用
- 原文结论指出,鉴于2018年分配评分变化,在决定是否提供CF-LVAD作为桥接移植时应考虑并发症风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Continuous-flow left ventricular assist device (CF-LVAD) support is a mainstay in the hemodynamic management of patients with end-stage heart failure refractory to optimal medical therapy. In this report we evaluated waitlist complications and competing outcomes for CF-LVAD patients compared with primary transplant candidates listed for orthotopic heart transplantation at a single center. METHODS: All patients listed for orthotopic heart transplantation between 2006 and 2020 at our institution were retrospectively reviewed (CF-LVAD, 300; primary transplant, 244). Kaplan-Meier methodology with log-rank testing was used to evaluate survival outcomes. Terminal outcomes of death, delisting, and transplant were assessed as competing risks and compared between groups using Gray's test. Multivariable Fine-Gray regression was used to identify predictors of transplantation. RESULTS: One-year rates of transplant, delisting, and death were 48%, 8%, and 2%, respectively, for CF-LVAD patients and 45%, 15%, and 9%, respectively, for primary transplant (all P < .001). Waitlist mortality at 5 years was 4% among CF-LVAD patients and 13% for primary transplants. All-cause mortality after listing was lower for CF-LVAD patients (P = .017). There was no difference in posttransplant survival between groups (P = .250). On multivariable Fine-Gray regression stroke (P = .017), respiratory failure (P = .032), right ventricular failure (P = .019), and driveline infection (P = .050) were associated with decreased probability of transplantation. Posttransplant survival was not significantly worse for CF-LVAD patients who experienced device-related complications (P = .901). CONCLUSIONS: Although device-related complications were significantly associated with decreased rates of transplant, CF-LVAD patients had excellent waitlist outcomes overall. In light of the 2018 allocation score change the risk of complications should be taken into account when deciding whether to offer CF-LVAD as a bridge to transplant.
引用
- Bakir NH, Finnan MJ, Itoh A, et al. Competing Risks to Transplant in Bridging With Continuous-flow Left Ventricular Assist Devices. Ann Thorac Surg. 2021. PMID: 34808111. doi:10.1016/j.athoracsur.2021.09.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。